Fulltext

Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study

Lim KS 1 , Lotay N 2 , White R 3 , Kwan P 4

Affiliations 

  • 1 Division of Neurology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: kslimum@gmail.com
  • 2 Neurosciences, GlaxoSmithKline Research and Development, Uxbridge, UK. Electronic address: narinder.k.lotay@gsk.com
  • 3 GlaxoSmithKline, Durham, NC, USA. Electronic address: Robin.White@parexel.com
  • 4 Departments of Medicine and Neurology, University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia; Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China. Electronic address: patrick.kwan@unimelb.edu.au
Epilepsy Behav, 2016 Jul 1;61:224-230.
PMID: 27376872 DOI: 10.1016/j.yebeh.2016.05.018

Abstract

The purpose of this study was to evaluate the efficacy and safety of adjunctive retigabine/ezogabine (RTG/EZG) therapy in Asian adults with partial-onset seizures.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications